Considering the many differences of AGT between humans and mice, it is necessary to determine whether the impressive atherosclerosis reductive effects by AGT inhibition in mice can be reproduced in humans or a human-like large animal model such as nonhuman primates.15 Most importantly, mouse atherosclerosis does not fully recapitulate the manifestations of human atherosclerosis.64 With the availability of human GalNAc AGT ASO and AGT siRNA,26,65 clinical trials on targeting liver AGT to treat human atherosclerotic disease are now feasible. This evidence concerns the gene AGT and atherosclerosis.